Market Research Logo

Tetanus - Pipeline Review, H2 2015

Tetanus - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Tetanus - Pipeline Review, H2 2015’, provides an overview of the Tetanus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tetanus
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tetanus and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tetanus pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tetanus
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Tetanus Overview
Therapeutics Development
Pipeline Products for Tetanus - Overview
Pipeline Products for Tetanus - Comparative Analysis
Tetanus - Therapeutics under Development by Companies
Tetanus - Therapeutics under Investigation by Universities/Institutes
Tetanus - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Tetanus - Products under Development by Companies
Tetanus - Products under Investigation by Universities/Institutes
Tetanus - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co., Ltd
Bharat Biotech International Limited
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Green Cross Corporation
Indian Immunologicals Limited
LG Life Sciences, Ltd.
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited
Tetanus - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(diphtheria + tetanus + pertussis) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-1107 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-5I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VN-0103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tetanus - Recent Pipeline Updates
Tetanus - Dormant Projects
Tetanus - Discontinued Products
Tetanus - Product Development Milestones
Featured News & Press Releases
Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series.
Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Tetanus, H2 2015
Number of Products under Development for Tetanus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015
Tetanus - Pipeline by Bharat Biotech International Limited, H2 2015
Tetanus - Pipeline by Biological E. Limited, H2 2015
Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015
Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2015
Tetanus - Pipeline by Green Cross Corporation, H2 2015
Tetanus - Pipeline by Indian Immunologicals Limited, H2 2015
Tetanus - Pipeline by LG Life Sciences, Ltd., H2 2015
Tetanus - Pipeline by Panacea Biotec Limited, H2 2015
Tetanus - Pipeline by Prometheon Pharma, LLC, H2 2015
Tetanus - Pipeline by Sanofi, H2 2015
Tetanus - Pipeline by Sanofi Pasteur SA, H2 2015
Tetanus - Pipeline by Serum Institute of India Limited, H2 2015
Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2015
Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Tetanus Therapeutics - Recent Pipeline Updates, H2 2015
Tetanus - Dormant Projects, H2 2015
Tetanus - Dormant Projects (Contd..1), H2 2015
Tetanus - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Tetanus, H2 2015
Number of Products under Development for Tetanus - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report